Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'd say between 5m and 15m max , and they would just be unsettled rather than
part of LG's mythical Chinese share certificate printer gangs.
I think its probably looking at trading patterns , eg I can often tell if something is algo , or short covering or new position with pretty good accuracy .
Compliance are bound to investigate anything and everything thats credible and believe me a law suit is as credible as it gets .
Right now as we speak they will already know if their PM's have been up to games .
They will be bound to report to to the regulator. AND ARE PROHIBITED FROM COMMUNICATING WITH EXECUTIVE MANAGEMENT , however of course they will and will inform them whats happened. .
Executive management will hand it over to the regulators immediately, blame , the traders or clients or both , then get hammered. on the lack of systems and controls governance , write a cheque to the regulator and do a deal with NWBO .
Regarding any fines or settlements amounts its a p in the ocean to them but they will want rid of it believe me .
Extremely easy .
Every single institution has to supply data on who executes the trade and who gives the trade order , (passport, finger prints , proof. they are. individually regulated etc etc ) also who the decision maker was , also recipient of funds and final recipient of funds .
Contrary to utter rubbish some other ' experts ' here are saying this is the process :
Lawsuit served .
Compliance and internal audit immediately notified internally or will have seen the news .
Go onto the system. search NWBO cancelled trades , they will immediately see the reasons or other wise for the cancellation or if it was a client . ONE HOUR MAXIMUM START TO FINISH
The MM would be no less culpable if it was a HF pulling their strings
Utter rubbish, based on what ?
FACT : He's been out of the picture for years apart from the odd ASM / ASCO cameo .
They are not short any fake shares. thats a phantom , a myth utter. verbal diarrhoea....
the market is electronic , end of ....
Ken Griffin would not know the name of the perpetrators boss's boss's boss , they have 2500. employees .
Compliance will look, if there are cancelled trades without a reason, whoever did the trades is in big trouble as would be their boss and maybe even one rung higher .
If it was client driven they'd still be screwed but so would the client .
Nope, on every point .
Anyway i dont care. .... bye
What on earth are you talking about , double down on cancelled trades , sounds like you havent got a clue how the market regulators and compliance works in financial services.
...any settlement will take years and we will never see a penny but for me its not about that its about allowing the market to find its correct level .
On this hideous exchange that would be $3-$5 .... On nasdaq NYSE / LSE that would be $5-$8
The compliance departments of every named party will be all over the electronic records today .
Those that carried out this scumbag behaviour will be quaking in their boots, as this would not result in
a note on the file, its immediate suspensions and more likely than not career anding
Cancelled trades are fine on the odd occasion as mistakes happen, however systematic
cancelling following data release would be so easy prove its frankly almost unbelievable
Every single trade executed plus the work up plus the ensuing cancellation is electronically held for at least 7 years I believe .
The law suit should allow discovery and that data will take under an hour to identify.
There is no way to hide cancelled trades due to the software MM are obliged to comply with.
In short if they walked the price down and then systematically cancelled the trades. they will all be caught very easily indeed.
Duplicate
Whichever MM were buying or selling doesn't make a blind bit of difference ,
right now I could give buy and sell orders to any or all of 16 of them and then reverse the orders at the click of a mouse .... so don`t waste your time , zero to be learned .
Stat News hit piece DID NOT appear on BBG News Heat .
You`ll see the AI toggle bar at the top , and you can see I`ve got mine set to allow anything and everything .
When the 10/5/22 hit piece was published it appeared all over the Bloomberg `News Heat` page , at the time I immediately complained, showing them screen shots of the presentation , their response to me in writing at the time was Stat News are an accredited news vendor and that the piece was quite obviously clock bait , so `tough`...
Ofcourse the ramification of his hit piece and the concerted selling of 6m shares on the bid and consequential 14% headline ... did appear
*MERCK & CO. TO BUY
IMAGO BIOSCIENCES FOR $36/SHR IN CASH
Precisely I`d actually be inclined to go for 1 for 20
Every trade that's currently going through is 100% retail .
...but when the first institutional / real money buyer comes in believe me we'll all know about it ..
Not Cleaing houses , its their PB's but you are in general correct ...
Estevito WHERE DID YOU SEE THAT ? LINK PLEASE
“Astonishing” results for brain tumour vaccine trial
https://www.braintumourresearch.org/media/news/news-item/2022/11/18/astonishing-results-for-brain-tumour-vaccine-trial
Brain Tumour Research
18 November 2022
Following being published in the high impact science journal JAMA Oncology, The Guardian has reported on a global clinical trial which has concluded that the world’s first vaccine to treat glioblastoma can potentially give patients years of extra life.
According to the paper the breakthrough could benefit the 2,500 people a year in the UK who are diagnosed with glioblastoma (GBM) who live on average just 12-18 months after diagnosis.
Professor Keyoumars Ashkan, a neurosurgeon at King’s College hospital in London who was the European chief investigator of the trial said: “The final results of this phase three trial … offer fresh hope to patients battling with glioblastoma.”
The vaccine “was shown to prolong life and interestingly so in patients traditionally considered to have poorer prognosis” he added, such as older people and people for whom surgery was not an option.
If approved by medical regulators, the vaccine, DCVax, would be the first new treatment in 17 years for newly diagnosed glioblastoma patients and the first in 27 years for people in whom it had returned.
The Guardian approached Brain Tumour Research for comment on this news and Dr Karen Noble our Director of Research, Policy and Innovation said:
“Now this vaccine trial data have been peer-reviewed and published in a scientific journal the pathway should be set up for a route to the bedside of more patients who have been starved of new clinical options for too long.
“DCVax-L represents the first emerging therapy proven effective in treating GBM since temozolomide chemotherapy in 2005 and what the brain tumour community hopes is for it to be affordable, possibly becoming standard of care - so available on the NHS."
Related Reading:
UK production for GBM vaccine begins
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.
Yep that'd do the trick
WE IMMEDIATELY NEED :
1.US Media coverage
2.1 for 10 reverse and uplist same day
3.Street Coverage ( which would automatically follow uplisting )
The Guardian , is a top end UK daily national broad sheet , and highly reputable
New data shows Guardian is the top quality and most trusted newspaper in the UK
GNM press office
Wed 17 Jun 2020 13.00 BST
The latest PAMCo results show the Guardian is the most read quality news publisher in the UK, with a record 35.6 million adults accessing Guardian journalism across both digital and print formats on average per month.
The Guardian is the second most-read online newspaper in the UK, overtaking the Mail (33.6m) for the third time in last four PAMCo releases, and the Mirror (31.7m), with a 46% year-on-year increase to bring the monthly digital readership to 35.2m readers.
The Guardian also retains its position as the UK’s most trusted news publisher by its regular readers at an overall brand level - encompassing both the Guardian and Observer in print and online.
The PAMCo data also demonstrates the Guardian’s increasingly regular and engaged readership - with the Guardian recording the largest daily (8.8m) cross-platform reach across all UK qualities - around double the nearest rivals of the Independent (5.3m) and The Telegraph (4.2m). On average digital readers spend 31 minutes per month with Guardian journalism - more than any other quality.
Katharine Viner, editor-in-chief, Guardian News & Media:
“During the coronavirus pandemic, the Guardian has consistently published the most impactful investigations, news and analysis, holding the government to account. We now have a record number of people coming to the Guardian and choosing to support us financially and it’s clear from this data that Guardian journalism is increasingly in demand, trusted and valued.”
The Guardian is also the most-read quality newsbrand - ahead of The Times, Telegraph, i and Independent – among key advertising demographics including women, men, ABC1, under 35s and families.
NWBO v Immunomedics Study
See below , IMMU were pre Ph3, pre revenue and of course miles form approval.
In Q2 2020 they had a m/c of $2bn ( which is kind of where we'd be if we were not on the OTC exchange ) and IMMU were bought out for $21bn in Q3 by Gilead .
Ponder this , market size of the triple negative breast cancer that IMMU treats vs nGBM and rGBM
NWBO v Immunomedics Study
See below , IMMU were pre Ph3, pre revenue and of course miles form approval.
In Q2 2020 they had a m/c of $2bn ( which is kind of where we'd be if we were not on the OTC exchange ) and IMMU were bought out for $21bn in Q3 by Gilead .
Ponder this , market size of the triple negative breast cancer that IMMU treats vs nGBM and rGBM
NHS negotiations
https://www.bbc.com/news/health-63540179
BARCLAYS ob Merck & Co., Inc.
3Q22: Post-Call Thoughts; Raising PT to $110
Five reasons we think MRK can still work even up here.
Merck again delivered a clean beat and raise, dialing up the same formula that has worked all year: Keytruda and Gardasil outperformance. While US performance drove the beats for both products (3Q22 Initial Impressions, 10/27/2022), OUS performance was solid in the face of
massive Fx headwinds – which bodes well for ‘23 estimates as Fx headwinds anniversary. With that backdrop, we see five reasons MRK shares will continue to work: (1) robust growth ex-
Lagevrio for ‘23: we model $57.7bn in Revs (implying +7% y/y growth - well towards the high-end of peers) as we expect Keytruda to grow 16% to $24.4bn and Gardasil to reach $7.5bn
(9% y/y), (2) outside chance of growing the top-line even inclusive of Lagevrio; that this is even in the discussion given the $5bn+ in Lagevrio ‘22 numbers shows the strength of the rest of the
business; a bigger step-up for OUS Keytruda/Gardasil and a Lagevrio print closer to the $1bn+ in cons and it could be achievable, (3) de-risking of the CV portfolio over the next 6-8 months (PCSK9, Factor XIA, MK-5475 phase 2 data, and full presentation of sotatercept STELLAR data are
all expected between now and 2Q23e), (4) subcut Keytruda data early next year should drive further conversations around adjuvant uptake (where the company has focused), but also on pushing timelines for biosimilar erosion beyond 2028 (where investors have focused), and (5)
Street continues to mismodel benefit to ‘24 margins from step-down in PD-1 royalty – a dynamic we expect will correct itself as timelines to ‘24 narrow. Maintain Overweight. Raising PT to $110.
Merck & Co Hits Record High at $96.74
YTD Change/% 21.14/27.58%
Mkt Cap (USD) $ 248 Bn
Positive Data with Zero Revenue Comparator Study :
1. Cerevel released positive TLD just over 15 months ago .
2. Their average market cap since the data release has been about $5bn
3. They recently issues $250m new shares PLUS $250m of converts
4. Like for like we should settle at least 50% above their average so $7-8bn m/c or $5.50 pps This estimate accounts for the positives of our manufacturing , but the negatives of being on OTC. (FYI getting up listed will be at least a 3 - 6 month process only starting once we are above $4)
Accelerated-Approval Changes Possible
Duane Wright, the primary analyst for this report.
Duane Wright
Team: Government
BI Senior Government Analyst
Lighter Accelerated-Approval Pathway Reforms Likely by Year End
Biogen, Roche and other drug makers should expect Congress to pass watered-down reforms to the accelerated-approval pathway during the lame duck session, leaving largely intact the program's foundations. More onerous reforms, like sun-setting accelerated approval, are likely off the table as Congress works toward a solution that favors industry. (10/19/22)
1. Watered-Down Accelerated-Approval Reforms Likely
Additional Reading:
CDER List of Accelerated-Approval Drugs and Biologics
Food and Drug Amendments of 2022
We give a 70% probability that Congress passes watered-down reforms to the accelerated-approval pathway during the lame duck session, which should largely favor industry in the long run by removing the overhang of more burdensome changes to the program. We anticipate legislation to require earlier design of confirmatory trials and provide FDA authority to require trials be underway at the time of approval. The legislation will likely allow drugmakers to use real-world evidence to support post-approval studies, filling evidence gaps during the confirmatory trial stage.
Even though Congress passed a FDA reauthorization bill over the summer, there is continuing support for modest reforms to the accelerated-approval pathway with a focus on drugs that spend years on the market without post-approval evidence. (10/19/22)
2. Significant Legislative Reforms Off the Table
Additional Reading:
Accelerated-Approval Payment Reforms
Accelerated-Approval Integrity Act of 2022
More onerous legislative reforms to the accelerated-approval pathway are likely off the table, maintaining a level of predictability for the program. Reforms such as automatic expiration of accelerated approval for drugs without completed confirmatory trials, or granting FDA authority to withdraw approval of an accelerated-approval product that fails to meet enrollment targets, milestones, or timely study completion, aren't in play. The latter could have been a high bar for companies given the number of trials that fail to meet clinical trial-enrollment timelines -- 80% by some estimates -- and fail to meet clinical trial-enrollment targets -- almost 50%.
Limiting Medicaid or Medicare reimbursement until confirmatory trials are completed and traditional approval is granted also appears unlikely. (10/19/22)
3. Administrative Reforms Possible
Additional Reading:
Executive Order on Lowering Drug Prices
Comprehensive Plan for Addressing High Drug Prices
It's possible the Biden administration could enact regulatory reforms that use innovative payment arrangements for drugs approved through the accelerated pathway. We're keeping an eye on Biden's drug pricing Executive Order (EO) that requires the Centers for Medicare and Medicaid Innovation to outline payment models that will test the feasibility of lowering costs for innovative drugs used in Medicare and Medicaid. Though no new authority is granted in the EO, it signals additional steps the administration may take to lower drug costs that go beyond the drug-pricing provisions in the Inflation Reduction Act. We anticipate the recommendations to be smaller scale in nature, with a potential focus on drugs approved through the accelerated-approval pathway by linking reimbursement to outcomes. (10/19/22)
FULL BNOS Presentation :
… also note NVCR gets outed for the piece of
garbage it is….
Of course , like you I would love that to be the case but Seagen are projected to bring in $2.5Bn revenue in 2023 and have a current m/c of $24.5Bn ,
Net net with even generous PV of future revenues we'd be about $14bn or $10 pps as we stand (post Journal , Applications , Global PR etc )
Heard on the Street: Merck's Patent Cliff Doesn't Look So Frightening Anymore -- WSJ
By David Wainer
(Dow Jones) -- Many of the country's largest pharmaceutical companies, from Merck & Co. to Bristol-Myers Squibb, are under pressure to do deals right now because they are staring at huge patent cliffs for their top-selling drugs.
For investors considering whether to buy into these companies, figuring out which management teams are going to make the right acquisitions is a bit of a crapshoot. It can be difficult to build a financial model for a company without knowing who it will acquire. Further uncertainty comes from the fact that many pharma acquisitions involve drugs still in development. So the next best thing can be to look at management's acquisition track record. In that respect, Merck just earned some credibility with investors.
The crown jewel of its $11.5 billion purchase last year of Acceleron Pharma is a drug called Sotatercept for a rare type of high blood pressure known as pulmonary arterial hypertension (PAH). Sotatercept appeared to deliver positive results, potentially paving the way for a multibillion-dollar drug.
Merck said Monday that the late-stage trial of the drug for PAH met its primary endpoint, significantly extending how far patients could walk in six minutes compared with a placebo. The company added that eight of nine secondary endpoints achieved statistical significance. It didn't disclose detailed results, which will be presented at a coming conference.
Jared Holz, a healthcare-sector specialist at Oppenheimer, says any management team is going to be judged by how well their last major acquisition has fared. And right now, making smart deals is as important as ever for the industry because more than $200 billion in annual drug sales could face competition from generics later this decade as patent protection for top-selling medicines expires. "The sector depends on business development in a way that it hasn't in a while," says Mr. Holz.
Merck is perhaps the company with one of the biggest holes to fill. Its top drug, Keytruda, is going off patent in 2028, at which point it is expected to have been generating north of $30 billion in sales, amounting to about 50% of the company's forecast revenue.
A key part of its strategy to replenish its product line is to rebuild its cardiovascular and pulmonary portfolio, for which Merck has set a target of eight approved drugs bringing in about $10 billion in sales in 2030. That is an ambitious goal that is by no means assured, but it is part of a broader trend as the heart-drug market makes a comeback. Drugmakers are investing in a generation of new products after many blockbuster drugs for things like blood pressure and cholesterol faced generic competition.
Sotatercept can't replace Keytruda alone, of course. If the drug is approved, Guggenheim analysts see it fetching sales of about $4 billion in 2031. But Sotatercept's success could help win investor trust in Chief Executive Rob Davis as his team looks for its next acquisition.
Merck has engaged in intensive talks to acquire biotechnology firm Seagen for about $40 billion in recent months, but it is unclear whether that deal has been called off. Several other biotechs, including Argenx, BioMarin Pharmaceutical, Alnylam Pharmaceuticals and Biogen could present attractive targets for Merck and other big pharma companies.
As in the case of Acceleron, it often takes some time for investors to know for certain if a deal will pan out. In the meantime, management teams need all the support they can get, and it helps when their most recent deal shows signs of panning out.
Write to David Wainer at david.wainer@wsj.com
This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (October 12, 2022).
(END) Dow Jones Newswires